No connection

Search Results

ARVN vs KURA

ARVN
Arvinas, Inc.
BEARISH
Price
$12.18
Market Cap
$782.3M
Sector
Healthcare
AI Confidence
85%
KURA
Kura Oncology, Inc.
BEARISH
Price
$8.67
Market Cap
$765.8M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ARVN
--
KURA
--
Forward P/E
ARVN
-3.49
KURA
-3.55
P/B Ratio
ARVN
1.78
KURA
4.37
P/S Ratio
ARVN
2.98
KURA
11.35
EV/EBITDA
ARVN
-0.92
KURA
-0.39

Profitability

Gross Margin
ARVN
100.0%
KURA
-272.14%
Operating Margin
ARVN
-754.74%
KURA
-497.62%
Profit Margin
ARVN
-30.77%
KURA
0.0%
ROE
ARVN
-16.23%
KURA
-94.82%
ROA
ARVN
-7.94%
KURA
-25.33%

Growth

Revenue Growth
ARVN
-84.0%
KURA
-67.8%
Earnings Growth
ARVN
--
KURA
--

Financial Health

Debt/Equity
ARVN
0.02
KURA
0.12
Current Ratio
ARVN
4.92
KURA
6.06
Quick Ratio
ARVN
4.86
KURA
5.81

Dividends

Dividend Yield
ARVN
--
KURA
--
Payout Ratio
ARVN
0.0%
KURA
0.0%

AI Verdict

ARVN BEARISH

ARVN's Advanced Deterministic Scorecard reveals severe financial distress: a Piotroski F-Score of 0/9 indicates extreme operational weakness, and the absence of an Altman Z-Score suggests no solvency validation. Despite a strong gross margin of 100.00%, the company reports a -30.77% profit margin, -754.74% operating margin, and an 84% YoY revenue decline, signaling fundamental business deterioration. Insider selling activity totaling $0.83M over six months, with multiple officer and CEO sales, reinforces bearish sentiment. While the stock has rebounded 42.5% over the past year, this is likely driven by speculative momentum rather than fundamentals, and the current price of $12.18 remains elevated relative to its deteriorating performance.

Strengths
Gross margin of 100.00% indicates potential product pricing power or low production costs
Extremely low debt/equity ratio of 0.02 suggests minimal financial leverage risk
High current and quick ratios (4.92 and 4.86) reflect strong short-term liquidity
Risks
Piotroski F-Score of 0/9 signals severe financial distress and operational failure
84% YoY revenue decline and negative operating margin (-754.74%) indicate business contraction and unsustainable operations
Insider selling of $0.83M in the last 6 months, including CEO and officer sales, signals loss of confidence
KURA BEARISH

KURA presents a contradictory profile with a stable Piotroski F-Score of 6/9 and exceptional liquidity (Current Ratio 6.06), yet suffers from severe fundamental decay. The company has experienced a catastrophic revenue decline of -67.80% YoY and has missed earnings estimates in four consecutive quarters with an average surprise of -50.91%. While the analyst target price of $31.82 suggests significant upside, this is decoupled from the current financial reality of negative gross margins (-272.14%) and bearish insider activity. The stock is currently a speculative play on pipeline success rather than a value or growth investment based on existing data.

Strengths
Strong liquidity position with a Current Ratio of 6.06
Very low leverage with a Debt/Equity ratio of 0.12
Stable Piotroski F-Score (6/9) indicating baseline operational stability
Risks
Severe revenue contraction (-67.80% YoY and Q/Q)
Consistent earnings misses (0/4 beats in the last year)
Deeply negative profitability (Operating Margin -497.62%)

Compare Another Pair

ARVN vs KURA: Head-to-Head Comparison

This page compares Arvinas, Inc. (ARVN) and Kura Oncology, Inc. (KURA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile